Apellis Pharmaceuticals, Inc.
Clinical trials sponsored by Apellis Pharmaceuticals, Inc., explained in plain language.
-
New combo therapy aims to slow vision loss from dry AMD
Disease control Recruiting nowThis study tests whether adding a new drug (APL-3007) to an existing treatment (Syfovre) can better slow the progression of geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. About 240 adults aged 60 and older with the condition …
Phase: PHASE2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New drug aims to jumpstart transplanted kidneys faster
Disease control Recruiting nowThis study tests a drug called pegcetacoplan in 320 adults who are getting a kidney transplant from a deceased donor and are at high risk for delayed graft function (when the kidney takes a while to start working). Participants receive either the drug or a placebo after surgery. …
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC